Keynote-242

Keynote-242. Those that were treatment related occurred. Melanoma nct02506153 (swog1404) pembrolizumab os, rfs melanoma nct03553836 (keynote 716) pembrolizumab rfs melanoma nct03068455.

 — pembrolizumab was administered to patients at 200 mg every 3 weeks until unacceptable toxicity or confirmed disease progression.  — grade 3 or higher adverse events occurred in 147 (52.7%) and 62 patients (46.3%) for pembrolizumab versus placebo;